Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein

Clinical Cancer Research

Volumn 6, Issue 11, 2000, Pages 4416-4421

  Bardelmeijer, Heleen A ^a   Beijnen, Jos H ^b   Brouwer, Kenneth R ^c   Rosing, Hilde ^b   Nooijen, Willem J ^a   Schellens, Jan H M ^a   Van Tellingen, Olaf ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; ELACRIDAR; GLYCOPROTEIN P; PACLITAXEL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; DRUG BIOAVAILABILITY; DRUG PROTEIN BINDING; FEMALE; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ACRIDINES; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; FEMALE; ISOQUINOLINES; MICE; P-GLYCOPROTEIN; PACLITAXEL; TETRAHYDROISOQUINOLINES;

EID: 0033750523     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Taxanes: A new class of antitumor agents
2. The analysis and preliminary pharmacokinetics of Cremophor EL in human plasma
3. Hypersensitivity reactions from taxol
4. Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives
5. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL
6. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: Clinical pharmacokinetic implications
7. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients
8. Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice
9. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
10. Selective biotransformation of taxol to 6 a-hydroxytaxol by human cytochrome P450 2C8
11. Metabolism of taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and an unknown P450 enzyme
12. Taxol metabolism by human liver microsomes: Identification of cytochrome P450 isozymes involved in its biotransformation
13. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833
14. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A
15. Co-administration of cyclosporin enables oral therapy with paclitaxel
16. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel
17. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative
18. The acridonecarboxamide GF120918 potently reverses P-glycoprotein-mediated resistance in human sarcoma MES-Dx5 cells
19. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropy-Idibenzosuberane modulator, LY335979
20. Pharmacological characterization of LY335979: A potent cyclopropy-Idibenzosuberane modulator of P-glycoprotein
21. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein
22. BIRICODAR (VX-710; Incel): An effective chemosensitizer in neuroblastoma
23. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP
24. Normal viability and altered phannacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
25. Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography
26. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small cell lung cancer
27. In vitro and in vivo drug interactions involving human CYP3A
28. The mouse Bcrp1/Mxr/Abcp gene: Amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin
29. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter. MXR
30. The Role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice
31. Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated peffused rat liver
32. Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein
33. P-glycoprotein: A defense mechanism limiting oral bioavailability and CNS accumulation of drugs
34. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites
35. Disruption of the mouse mdr1a P-gtycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
36. Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice
37. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure